D. E. Shaw & Co., Inc. Aldeyra Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$125 Billion
Q2 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 487,672 shares of ALDX stock, worth $2.61 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

487,672

Previous 151,642 221.59%

Holding current value

$2.61 Million

Previous $871,000 114.35%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$1.42 - $5.48 $477,162 - $1.84 Million	336,030 Added 221.59%	487,672 $1.87 Million
Q1 2025 May 15, 2025	SELL	$4.7 - $6.98 $173,622 - $257,848	-36,941 Reduced 19.59%	151,642 $871,000
Q4 2024 Feb 14, 2025	SELL	$4.21 - $5.9 $615,493 - $862,568	-146,198 Reduced 43.67%	188,583 $941,000
Q3 2024 Nov 14, 2024	BUY	$3.19 - $6.32 $40,969 - $81,167	12,843 Added 3.99%	334,781 $1.8 Million
Q2 2024 Aug 14, 2024	SELL	$3.25 - $4.72 $733,531 - $1.07 Million	-225,702 Reduced 41.21%	321,938 $1.07 Million
Q1 2024 May 15, 2024	BUY	$2.77 - $4.22 $796,607 - $1.21 Million	287,584 Added 110.59%	547,640 $1.79 Million
Q4 2023 Feb 14, 2024	BUY	$1.47 - $6.06 $314,710 - $1.3 Million	214,089 Added 465.74%	260,056 $912,000
Q3 2023 Nov 14, 2023	SELL	$6.11 - $8.16 $183,379 - $244,906	-30,013 Reduced 39.5%	45,967 $307,000
Q2 2023 Aug 14, 2023	SELL	$7.11 - $11.89 $347,977 - $581,920	-48,942 Reduced 39.18%	75,980 $637,000
Q1 2023 May 15, 2023	SELL	$5.77 - $9.93 $1.29 Million - $2.21 Million	-222,947 Reduced 64.09%	124,922 $1.24 Million
Q4 2022 Feb 14, 2023	SELL	$5.08 - $7.09 $509,224 - $710,708	-100,241 Reduced 22.37%	347,869 $2.42 Million
Q3 2022 Nov 14, 2022	BUY	$3.8 - $7.74 $664,122 - $1.35 Million	174,769 Added 63.94%	448,110 $2.39 Million
Q2 2022 Aug 15, 2022	BUY	$2.43 - $4.85 $83,064 - $165,787	34,183 Added 14.29%	273,341 $1.09 Million
Q1 2022 May 16, 2022	BUY	$3.25 - $5.17 $659,522 - $1.05 Million	202,930 Added 560.15%	239,158 $1.06 Million
Q4 2021 Feb 14, 2022	BUY	$3.5 - $9.63 $76,814 - $211,349	21,947 Added 153.68%	36,228 $145,000
Q3 2021 Nov 15, 2021	SELL	$7.94 - $11.31 $7,479 - $10,654	-942 Reduced 6.19%	14,281 $125,000
Q2 2021 Aug 16, 2021	SELL	$10.44 - $14.85 $30,578 - $43,495	-2,929 Reduced 16.14%	15,223 $172,000
Q1 2021 May 17, 2021	BUY	$6.53 - $14.42 $118,532 - $261,751	18,152 New	18,152 $216,000
Q4 2019 Feb 14, 2020	SELL	$4.73 - $7.98 $85,665 - $144,525	-18,111 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$4.41 - $6.12 $30,900 - $42,882	7,007 Added 63.1%	18,111 $95,000
Q2 2019 Aug 14, 2019	BUY	$6.0 - $9.0 $66,624 - $99,936	11,104 New	11,104 $67,000

Others Institutions Holding ALDX

# of Institutions

136

Shares Held

34.9M

Call Options Held

263K

Put Options Held

51.6K

View Full List

About Aldeyra Therapeutics, Inc.

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $313M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

More about ALDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account